Dimerix Limited · ASX:DXB
Dimerix — Investor Presentation (November 2022)
18 slides from Dimerix's investor presentation, Nov 23, 2022
Slide 1: Investor Briefing Notice
For Immediate Release INVESTOR BRIEFING NOTICE For personal use only MELBOURNE, Australia, 23 November 2022: Dimerix Limited (ASX: DXB) (“Dimerix” or the “Company”), a clinical-stage biopharmaceutical company with multiple late-stage clinical assets, is pleased to invite investors to a live webinar
Slide 2: About Dimerix
About Dimerix Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complic
Slide 3: Dimerix Investor Presentation November 2022
@w Dimerix (ASX:DXB) Investor Presentation November 2022 coed BF F5GS7 Nd 4, S 713991 yy? Authorised for lodgment by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 5: About Dimerix
About Dimerix Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease Lead Drug Candidate Oma Sia Ready DMxX-200 Strong Pipeline Demonstr
Slide 6: Share price and shareholders
For personal use only Share price Shareholders *includes R&D Incentive Refund $6m received post quarter end
Slide 7: Development pipeline
Development pipeline Program Indication Preclinical Phase1 Phase2 Phase3 Key milestones Phase 2 demonstrated promising efficacy and safety’, next study planned Diabetic Kidney Disease with support form Australian Centre for Diabetes Innovation; anticipated DMX-200 i Study recruitment across Europe,
Slide 8: For personal use only
2,500.00 For personal use only REG 1x P3 Ren Reg 1x P3 Ren 2,000.00 WW 1x P1 Ren WW 1x P2 Mul 1,500.00 CTRY 1x P3 Ren CTRY 1x P2 Ren 1,000.00 WW 1x P3 Ren Reg 1x Pre Ren 500.00 Reg 1x Pre Ren WW 1x P1 Ren 0.00 Jan-20 Apr-20 Aug-20 Nov-20 Feb-21 Jun-21 Sep-21 Dec-21
Slide 9: Renal disease landscape
Renal disease landscape ‘A squeaky wheel waiting for grease: 50 years of kidney disease management in the US” Historical lack of incentives and public policy have |contributed to high costs and| poor health outcomes for renal patients! 2018: workshops and regulatory acceptance of surrogate end point
Slide 10: Policy change: renal disease healthcare economic burden
Policy change: renal disease healthcare economic burden “40 million adults have kidney / disease (“15% of the adult population) in the US in 20211 2019 White House executive order issued: incentives for providers to delay patient progression to renal failure 2 @w Dimerix US$88 billion estimated tota
Slide 11: Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis | healthy kidney has little to no protein in the urine Focal =some q Inside a healthy kidney Inside a damaged kidney Segmental = sections blood blood Glomerulo = of the kidney filtering units filter i Sclerosis = are scarred urine cy oe \ = | A ) . = y ' ° = Protei
Slide 12: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease ATIR — blocked by angiotensin receptor blocker (ARB) CCR2 —CCR2 is the receptor for MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys? 1 Hyperfiltration of and hypertension within blood vessels of the glomerul
Slide 13: Phase 3 studies investigating FSGS treatments
Phase 3 studies investigating FSGS treatments No therapies yet approved specifically for FSGS Drug candidate Primary interim (accelerated approval) endpoint ACTION3" DMX-200 CCR2 inhibitor Placebo Percent change in uPCR and eGFR slope at week 35 Dual Proportion of patients achieving uPCR < 1.5g/g an
Slide 14: DMX-200 working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) Small molecule Clear Development Path [Easy and convenient dosing Extensive regulatory engagement New Chemical Entity
Slide 15: ACTION3 FSGS Phase 3 study design
O ACTIONS - FSGS phase 3 study design FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB ARB stabilisation Treatment period weeks -6 1 0 35 104 ' ! c i = ca 2 DMX-200 @ rt = & 21] —€ 5 Ff io] ® 3
Slide 16: ACTION3 FSGS Phase 3 study locations
O ACTICING - FSGS phase 3 study locations — Part 1 FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Global study recruiting across “70 sites: ° Australasia: 9 sites ° Asia: 9 sites ° Europe 18 s
Slide 17: ACTION3 Study Part 1 recruitment status
OQ ACTICING Study part 1 recruitment status FSGS CLINICAL STUDY Patients recruited*: * On track to complete Part 1 recruitment and 100% dosing Q4 2022 Estimated * Part 1 completion anticipated mid-2023** 90% 80% 70% 60% 50% 40% 30% 20% | Northern hemisphere summer holiday 10% - r + Start up activiti
Slide 18: Dimerix
Dimerix A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. Lead phase 3 program to report mid 2023 Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T